Plethora, Shionogi deal

Plethora will assume worldwide registration and commercialization responsibilities for PSD502, excluding North and South America, Japan, Korea, China and Taiwan, after it and Shionogi's Sciele Pharma Inc. subsidiary amended a 2007 deal. The deal was amended twice in 2009 to grant Sciele U.S. development rights to the topical analgesic spray containing lidocaine and prilocaine, and then full worldwide rights. Shionogi is eligible to receive undisclosed royalties (see BioCentury, May 28, 2007; April 6, 2009 & June 1, 2009). ...